47 results on '"Spearman, C Wendy"'
Search Results
2. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus
- Author
-
Zeng, Xu-Fen, Varady, Krista A., Wang, Xiang-Dong, Targher, Giovanni, Byrne, Christopher D., Tayyem, Reema, Latella, Giovanni, Bergheim, Ina, Valenzuela, Rodrigo, George, Jacob, Newberry, Carolyn, Zheng, Ju-Sheng, George, Elena S., Spearman, C. Wendy, Kontogianni, Meropi D., Ristic-Medic, Danijela, Peres, Wilza Arantes Ferreira, Depboylu, Gamze Yurtdaş, Yang, Wanshui, Chen, Xu, Rosqvist, Fredrik, Mantzoros, Christos S., Valenti, Luca, Yki-Järvinen, Hannele, Mosca, Antonella, Sookoian, Silvia, Misra, Anoop, Yilmaz, Yusuf, Kim, Won, Fouad, Yasser, Sebastiani, Giada, Wong, Vincent Wai-Sun, Åberg, Fredrik, Wong, Yu Jun, Zhang, Pianhong, Bermúdez-Silva, Francisco-Javier, Ni, Yan, Lupsor-Platon, Monica, Chan, Wah Kheong, Méndez-Sánchez, Nahum, de Knegt, Robert J., Alam, Shahinul, Treeprasertsuk, Sombat, Wang, Li, Du, Mulong, Zhang, Tiejun, Yu, Ming-Lung, Zhang, Huijie, Qi, Xingshun, Liu, Xin, Pinyopornpanish, Kanokwan, Fan, Yu-Chen, Niu, Kaijun, Jimenez-Chillaron, Josep C., and Zheng, Ming-Hua
- Published
- 2024
- Full Text
- View/download PDF
3. Feasibility of implementing viral hepatitis services into a correctional service facility in Cape Town, South Africa
- Author
-
Scheibe, Andrew, Steingo, Joel, Grace, Gaynor, Savva, Helen, Sonderup, Mark, Hausler, Harry, and Spearman, C. Wendy
- Published
- 2025
- Full Text
- View/download PDF
4. Prevalence, management and outcomes of pulmonary metastases in hepatocellular carcinoma: a systematic review and meta-analysis
- Author
-
Emmamally, Muhammad, Sobnach, Sanju, Khan, Rufaida, Kotze, Urda, Bernon, Marc, Sonderup, Mark W., Spearman, C. Wendy, and Jonas, Eduard
- Published
- 2024
- Full Text
- View/download PDF
5. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease
- Author
-
Younossi, Zobair M., AlQahtani, Saleh A., Funuyet-Salas, Jesús, Romero-Gómez, Manuel, Yilmaz, Yusuf, Keklikkiran, Caglayan, Alswat, Khalid, Yu, Ming-Lung, Liu, Chun-Jen, Fan, Jian-Gao, Zheng, Ming-Hua, Burra, Patrizia, Francque, Sven M., Castera, Laurent, Schattenberg, Jörn M., Newsome, Philip N., Allen, Alina M., El-Kassas, Mohamed, Treeprasertsuk, Sombat, Hameed, Saeed, Wai-Sun Wong, Vincent, Zelber-Sagi, Shira, Takahashi, Hirokazu, Kawaguchi, Takumi, Castellanos Fernández, Marlen I., Duseja, Ajay, Arrese, Marco, Rinella, Mary, Singal, Ashwani K., Gordon, Stuart C., Fuchs, Michael, Eskridge, Wayne, Alkhouri, Naim, Cusi, Kenneth, Loomba, Rohit, Ranagan, Jane, Kautz, Achim, Ong, Janus P., Kugelmas, Marcelo, Eguchi, Yuichiro, Diago, Moises, Gerber, Lynn, Lam, Brian, Fornaresio, Lisa, Nader, Fatema, Spearman, C. Wendy, Roberts, Stuart K., Chan, Wah-Kheong, Silva, Marcelo, Racila, Andrei, Golabi, Pegah, Ananchuensook, Prooksa, Henry, Linda, Stepanova, Maria, Carrieri, Patrizia, and Lazarus, Jeffrey V.
- Published
- 2024
- Full Text
- View/download PDF
6. Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study
- Author
-
Minier, Nicolas, Guingané, Alice Nanelin, Okeke, Edith, Sinkala, Edford, Johannessen, Asgeir, Andersson, Monique I, Davwar, Pantong, Desalegn, Hailemichael, Duguru, Mary, Fall, Fatou, Mboup, Souleyman, Maponga, Tongai, Matthews, Philippa C, Ramírez Mena, Adrià, Ndow, Gibril, Orlien, Stian M S, Riches, Nicholas, Seydi, Moussa, Sonderup, Mark, Spearman, C Wendy, Stockdale, Alexander J, Taljaard, Jantjie, Vinikoor, Michael, Wandeler, Gilles, Lemoine, Maud, Shimakawa, Yusuke, and Sombié, Roger
- Published
- 2024
- Full Text
- View/download PDF
7. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
- Author
-
Younossi, Zobair M., Alqahtani, Saleh A., Alswat, Khalid, Yilmaz, Yusuf, Keklikkiran, Caglayan, Funuyet-Salas, Jesús, Romero-Gómez, Manuel, Fan, Jian-Gao, Zheng, Ming-Hua, El-Kassas, Mohamed, Castera, Laurent, Liu, Chun-Jen, Wai-Sun Wong, Vincent, Zelber-Sagi, Shira, Allen, Alina M., Lam, Brian, Treeprasertsuk, Sombat, Hameed, Saeed, Takahashi, Hirokazu, Kawaguchi, Takumi, Schattenberg, Jörn M., Duseja, Ajay, Newsome, Phil N., Francque, Sven, Spearman, C. Wendy, Castellanos Fernández, Marlen I., Burra, Patrizia, Roberts, Stuart K., Chan, Wah-Kheong, Arrese, Marco, Silva, Marcelo, Rinella, Mary, Singal, Ashwani K., Gordon, Stuart, Fuchs, Michael, Alkhouri, Naim, Cusi, Kenneth, Loomba, Rohit, Ranagan, Jane, Eskridge, Wayne, Kautz, Achim, Ong, Janus P., Kugelmas, Marcelo, Eguchi, Yuichiro, Diago, Moises, Yu, Ming-Lung, Gerber, Lynn, Fornaresio, Lisa, Nader, Fatema, Henry, Linda, Racila, Andrei, Golabi, Pegah, Stepanova, Maria, Carrieri, Patrizia, and Lazarus, Jeffrey V.
- Published
- 2024
- Full Text
- View/download PDF
8. Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa
- Author
-
Johannessen, Asgeir, Stockdale, Alexander J., Henrion, Marc Y. R., Okeke, Edith, Seydi, Moussa, Wandeler, Gilles, Sonderup, Mark, Spearman, C. Wendy, Vinikoor, Michael, Sinkala, Edford, Desalegn, Hailemichael, Fall, Fatou, Riches, Nicholas, Davwar, Pantong, Duguru, Mary, Maponga, Tongai, Taljaard, Jantjie, Matthews, Philippa C., Andersson, Monique, Mboup, Souleyman, Sombie, Roger, Shimakawa, Yusuke, and Lemoine, Maud
- Published
- 2023
- Full Text
- View/download PDF
9. Managing cirrhosis with limited resources: perspectives from sub-Saharan Africa
- Author
-
Sonderup, Mark W, Kamath, Patrick S, Awuku, Yaw A, Desalegn, Hailemichael, Gogela, Neliswa, Katsidzira, Leolin, Tzeuton, Christian, Bobat, Bilal, Kassianides, Chris, and Spearman, C Wendy
- Published
- 2024
- Full Text
- View/download PDF
10. A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Author
-
Rinella, Mary E., Lazarus, Jeffrey V., Ratziu, Vlad, Francque, Sven M., Sanyal, Arun J., Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F., Anstee, Quentin M., Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D., Narro, Graciela E. Castro, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R., Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D., Harrison, Stephen A., Kim, Seung Up, Koot, Bart G., Korenjak, Marko, Kowdley, Kris V., Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R., Powell, Elisabeth E., Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C., Spearman, C. Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B., Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, and Newsome, Philip N.
- Published
- 2024
- Full Text
- View/download PDF
11. The management and outcomes of hepatocellular carcinoma in sub-Saharan Africa: a systematic review
- Author
-
Sobnach, Sanju, Kotze, Urda, Spearman, C. Wendy, Sonderup, Mark, Nashidengo, Pueya R., Ede, Chikwendu, Keli, Elie, Chihaka, Onesai, Zerbini, Luiz F., Li, Yifan J., Gandhi, Karan, Krige, Jake, and Jonas, Eduard
- Published
- 2024
- Full Text
- View/download PDF
12. A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Author
-
Rinella, Mary E., Lazarus, Jeffrey V., Ratziu, Vlad, Francque, Sven M., Sanyal, Arun J., Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F., Anstee, Quentin M., Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D., Castro Narro, Graciela E., Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R., Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D., Harrison, Stephen A., Kim, Seung Up, Koot, Bart G., Korenjak, Marko, Kowdley, Kris V., Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R., Powell, Elisabeth E., Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C., Spearman, C. Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B., Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, and Newsome, Philip N.
- Published
- 2023
- Full Text
- View/download PDF
13. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
- Author
-
Razavi-Shearer, Devin, Gamkrelidze, Ivane, Pan, Calvin, Jia, Jidong, Berg, Thomas, Gray, Richard, Lim, Young-Suk, Chen, Chien-Jen, Ocama, Ponsiano, Desalegn, Hailemichael, Abbas, Zaigham, Abdallah, Ayat, Aghemo, Alessio, Ahmadbekova, Sabohat, Ahn, Sang Hoon, Aho, Inka, Akarca, Ulus, Al Masri, Nasser, Alalwan, Abduljaleel, Alavian, Seyed, Al-Busafi, Said, Aleman, Soo, Alfaleh, Faleh, Alghamdi, Abdullah, Al-Hamoudi, Waleed, Aljumah, Abdulrahman, Al-Naamani, Khalid, Al-Rifai, Ahmad, Alserkal, Yousif, Altraif, Ibrahim, Amarsanaa, Jazag, Anderson, Motswedi, Andersson, Monique, Armstrong, Paige, Asselah, Tarik, Athanasakis, Kostas, Baatarkhuu, Oidov, Ben-Ari, Ziv, Bensalem, Aicha, Bessone, Fernando, Biondi, Mia, Bizri, Abdul Rahman, Blach, Sarah, Braga, Wornei, Brandão-Mello, Carlos, Brosgart, Carol, Brown, Kimberly, Brown, Jr, Robert, Bruggmann, Philip, Brunetto, Maurizia, Buti, Maria, Cabezas, Joaquin, Casanovas, Teresa, Chae, Chungman, Chan, Henry Lik Yuen, Cheinquer, Hugo, Chen, Pei-Jer, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura, Coffin, Carla, Contreras, Fernando, Coppola, Nicola, Cornberg, Markus, Cowie, Benjamin, Cramp, Matthew, Craxi, Antonio, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris, Dalgard, Olav, De Knegt, Robert, De Ledinghen, Victor, Dore, Gregory, Drazilova, Sylvia, Duberg, Ann-Sofi, Egeonu, Steve, Elbadri, Mohammed, El-Kassas, Mohamed, El-Sayed, Manal, Estes, Chris, Etzion, Ohad, Farag, Elmobashar, Ferradini, Laurent, Ferreira, Paulo, Flisiak, Robert, Forns, Xavier, Frankova, Sona, Fung, James, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana, Gholam, Pierre, Gish, Robert, Goleij, Pouya, Gottfredsson, Magnus, Grebely, Jason, Gschwantler, Michael, Guingane, Nanelin Alice, Hajarizadeh, Behzad, Hamid, Saeed, Hamoudi, Waseem, Harris, Aaron, Hasan, Irsan, Hatzakis, Angelos, Hellard, Margaret, Hercun, Julian, Hernandez, Javier, Hockicková, Ivana, Hsu, Yao-Chun, Hu, Ching-Chih, Husa, Petr, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jelev, Deian, Jeruma, Agita, Johannessen, Asgeir, Kåberg, Martin, Kaita, Kelly, Kaliaskarova, Kulpash, Kao, Jia-Horng, Kelly-Hanku, Angela, Khamis, Faryal, Khan, Aamir, Kheir, Omer, Khoudri, Ibtissam, Kondili, Loreta, Konysbekova, Aliya, Kristian, Pavol, Kwon, Jisoo, Lagging, Martin, Laleman, Wim, Lampertico, Pietro, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice, Lee, Mei-Hsuan, Liakina, Valentina, Lukšić, Boris, Malekzadeh, Reza, Malu, Abraham, Marinho, Rui, Mendes-Correa, Maria Cássia, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mohamed, Rosmawati, Mokhbat, Jacques, Mooneyhan, Ellen, Moreno, Christophe, Mortgat, Laure, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Naveira, Marcelo, Negro, Francesco, Nersesov, Alexander, Nguyen, Van Thi Thuy, Ning, Qing, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin, Oguche, Stephen, Omuemu, Casimir, Ong, Janus, Opare-Sem, Ohene, Örmeci, Necati, Orrego, Mauricio, Osiowy, Carla, Papatheodoridis, George, Peck-Radosavljevic, Markus, Pessoa, Mário, Pham, Trang, Phillips, Richard, Pimenov, Nikolay, Pincay-Rodríguez, Loreley, Plaseska-Karanfilska, Dijana, Pop, Cora, Poustchi, Hossein, Prabdial-Sing, Nishi, Qureshi, Huma, Ramji, Alnoor, Rautiainen, Henna, Razavi-Shearer, Kathryn, Remak, William, Ribeiro, Sofia, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo, Robalino, Marcia, Roberts, Lewis, Roberts, Stuart, Rodríguez, Manuel, Roulot, Dominique, Rwegasha, John, Ryder, Stephen, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa, Salupere, Riina, Sanai, Faisal, Sanchez-Avila, Juan F, Saraswat, Vivek, Sargsyants, Narina, Sarrazin, Christoph, Sarybayeva, Gulya, Schréter, Ivan, Seguin-Devaux, Carole, Seto, Wai-Kay, Shah, Samir, Sharara, Ala, Sheikh, Mahdi, Shouval, Daniel, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta, Sinn, Dong Hyun, Sonderup, Mark, Sonneveld, Milan, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf, Stedman, Catherine, Sypsa, Vana, Tacke, Frank, Tan, Soek-Siam, Tanaka, Junko, Tergast, Tammo, Terrault, Norah, Thompson, Alexander, Thompson, Peyton, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsang, Tak-Yin, Uzochukwu, Benjamin, Van Welzen, Berend, Vanwolleghem, Thomas, Vince, Adriana, Voeller, Alexis, Waheed, Yasir, Waked, Imam, Wallace, Jack, Wang, Cong, Weis, Nina, Wong, Grace, Wong, Vincent, Wu, Jaw-Ching, Yaghi, Cesar, Yesmembetov, Kakharman, Yip, Terry, Yosry, Ayman, Yu, Ming-Lung, Yuen, Man-Fung, Yurdaydin, Cihan, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie
- Published
- 2023
- Full Text
- View/download PDF
14. A global research priority agenda to advance public health responses to fatty liver disease
- Author
-
Lazarus, Jeffrey V., Mark, Henry E., Allen, Alina M., Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A., Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N., Burra, Patrizia, Castro-Narro, Graciela E., Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M., Hagström, Hannes, Huang, Terry T-K., Wajcman, Dana Ivancovsky, Kautz, Achim, Kopka, Christopher J., Krag, Aleksander, Miller, Veronica, Newsome, Philip N., Rinella, Mary E., Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C. Wendy, Tsochatzis, Emmanuel A., Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M., Wong, Vincent Wai-Sun, Younossi, Zobair M., Aberg, Fredrik, Adams, Leon, Al-Naamani, Khalid, Albadawy, Reda M., Alexa, Zinaida, Allison, Michael, Alnaser, Faisal A., Alswat, Khalid, Alvares-da-Silva, Mario Reis, Alvaro, Domenico, Alves-Bezerra, Michele, Andrade, Raul J., Anstee, Quentin M., Awuku, Yaw Asante, Baatarkhuu, Oidov, Baffy, Gyorgy, Bakieva, Shokhista, Bansal, Meena B., Barouki, Robert, Batterham, Rachel L., Behling, Cynthia, Belfort-DeAguiar, Renata, Berzigotti, Annalisa, Betel, Michael, Bianco, Cristiana, Bosi, Emanuele, Boursier, Jerome, Brunt, Elizabeth M., Bugianesi, Elisabetta, Byrne, Christopher J., Cabrera Cabrejos, Maria Cecilia, Caldwell, Stephen, Carr, Rotonya, Castellanos Fernández, Marlen Ivón, Castera, Laurent, Castillo-López, Maria Gabriela, Caussy, Cyrielle, Cerda-Reyes, Eira, Ceriello, Antonio, Chan, Wah- Kheong, Chang, Yoosoo, Charatcharoenwitthaya, Phunchai, Chavez-Tapia, Norberto, Chung, Raymond T., Colombo, Massimo, Coppell, Kirsten, Cotrim, Helma P., Craxi, Antonio, Crespo, Javier, Dassanayake, Anuradha, Davidson, Nicholas O., De Knegt, Robert, de Ledinghen, Victor, Demir, Münevver, Desalegn, Hailemichael, Diago, Moises, Dillon, John F., Dimmig, Bruce, Dirac, M. Ashworth, Dirchwolf, Melisa, Dufour, Jean-François, Dvorak, Karel, Ekstedt, Mattias, El-Kassas, Mohamed, Elsanousi, Osama M., Elsharkawy, Ahmed M., Elwakil, Reda, Eskridge, Wayne, Eslam, Mohammed, Esmat, Gamal, Fan, Jian- Gao, Ferraz, Maria Lucia, Flisiak, Robert, Fortin, Davide, Fouad, Yasser, Freidman, Scott L., Fuchs, Michael, Gadano, Adrian, Gastaldelli, Amalia, Geerts, Anja, Geier, Andreas, George, Jacob, Gerber, Lynn H., Ghazinyan, Hasmik, Gheorghe, Liana, Kile, Denise Giangola, Girala, Marcos, Boon Bee, George Goh, Goossens, Nicolas, Graupera, Isabel, Grønbæk, Henning, Hamid, Saeed, Hebditch, Vanessa, Henry, Zachary, Hickman, Ingrid J., Hobbs, L. Ansley, Hocking, Samantha L., Hofmann, Wolf Peter, Idilman, Ramazan, Iruzubieta, Paula, Isaacs, Scott, Isakov, Vasily A., Ismail, Mona H., Jamal, Mohammad H., Jarvis, Helen, Jepsen, Peter, Jornayvaz, François, Sudhamshu, K.C., Kakizaki, Satoru, Karpen, Saul, Kawaguchi, Takumi, Keating, Shelley E., Khader, Yousef, Kim, Seung Up, Kim, Won, Kleiner, David E., Koek, Ger, Joseph Komas, Narcisse Patrice, Kondili, Loreta A., Koot, Bart G., Korenjak, Marko, Kotsiliti, Eleni, Koulla, Yiannoula, Kugelmas, Carina, Kugelmas, Marcelo, Labidi, Asma, Lange, Naomi F., Lavine, Joel E., Lazo, Mariana, Leite, Nathalie, Lin, Han-Chieh, Lkhagvaa, Undram, Long, Michelle T., Lopez-Jaramillo, Patricio, Lozano, Adelina, Macedo, Maria Paula, Malekzadeh, Reza, Marchesini, Giulio, Marciano, Sebastian, Martinez, Kim, Martínez Vázquez, Sophia E., Mateva, Lyudmila, Mato, José M., Nlombi, Charles Mbendi, McCary, Alexis Gorden, McIntyre, Jeff, McKee, Martin, Mendive, Juan M., Mikolasevic, Ivana, Miller, Pamela S., Milovanovic, Tamara, Milton, Terri, Moreno-Alcantar, Rosalba, Morgan, Timothy R., Motala, Ayesha, Muris, Jean, Musso, Carla, Nava-González, Edna J., Negro, Francesco, Nersesov, Alexander V., Neuschwander-Tetri, Brent A., Nikolova, Dafina, Norris, Suzanne, Novak, Katja, Ocama, Ponsiano, Ong, Janus P., Ong-Go, Arlinking, Onyekwere, Charles, Padilla, Martin, Pais, Raluca, Pan, Calvin, Panduro, Arturo, Panigrahi, Manas K., Papatheodoridis, Georgios, Paruk, Imran, Patel, Keyur, Gonçalves, Carlos Penha, Figueroa, Marlene Pérez, Pérez-Escobar, Juanita, Pericàs, Juan M., Perseghin, Gianluca, Pessoa, Mário Guimarães, Petta, Salvatore, Marques Souza de Oliveira, Claudia Pinto, Prabhakaran, Dorairaj, Pyrsopoulous, Nikolaos, Rabiee, Atoosa, Ramji, Alnoor, Ratziu, Vlad, Ravendhran, Natarajan, Ray, Katrina, Roden, Michael, Romeo, Stefano, Romero-Gómez, Manuel, Rotman, Yaron, Rouabhia, Samir, Rowe, Ian A., Sadirova, Shakhlo, Alkhatry, Maryam Salem, Salupere, Riina, Satapathy, Sanjaya K., Schwimmer, Jeffrey B., Sebastiani, Giada, Seim, Lynn, Seki, Yosuke, Serme, Abdel Karim, Shapiro, David, Sharvadze, Lali, Shaw, Jonathan E., Shawa, Isaac Thom, Shenoy, Thrivikrama, Shibolet, Oren, Shimakawa, Yusuke, Shubrook, Jay H., Singh, Shivaram Prasad, Sinkala, Edford, Skladany, Lubomir, Skrypnyk, Igor, Song, Myeong Jun, Sookoian, Silvia, Sridharan, Kannan, Stefan, Norbert, Stine, Jonathan G., Stratakis, Nikolaos, Sheriff, Dhastagir Sultan, Sundaram, Shikha S., Svegliati-Baroni, Gianluca, Swain, Mark G., Tacke, Frank, Taheri, Shahrad, Tan, Soek-Siam, Tapper, Elliot B., Targher, Giovanni, Tcaciuc, Eugen, Thiele, Maja, Tiniakos, Dina, Tolmane, Ieva, Torre, Aldo, Torres, Esther A., Treeprasertsuk, Sombat, Trenell, Michael, Turcan, Svetlana, Turcanu, Adela, Valantinas, Jonas, van Kleef, Laurens A., Velarde Ruiz Velasco, Jose Antonio, Vesterhus, Mette, Vilar-Gomez, Eduardo, Waked, Imam, Wattacheril, Julia, Wedemeyer, Heiner, Wilkins, Fonda, Willemse, José, Wong, Robert J., Yilmaz, Yusuf, Yki-Järvinen, Hannele, Yu, Ming-Lung, Yumuk, Volkan, Zeybel, Müjdat, Zheng, Kenneth I., Zheng, Ming-Hua, and Huang, Terry T.-K.
- Published
- 2023
- Full Text
- View/download PDF
15. Enhancing interventions for prevention of mother-to-child- transmission of hepatitis B virus
- Author
-
Matthews, Philippa C., Ocama, Ponsiano, Wang, Su, El-Sayed, Manal, Turkova, Anna, Ford, Deborah, Torimiro, Judith, Garcia Ferreira, Ana Cristina, Espinosa Miranda, Angélica, De La Hoz Restrepo, Fernando Pio, Seremba, Emmanuel, Mbu, Robinson, Pan, Calvin Q., Razavi, Homie, Dusheiko, Geoffrey, Spearman, C. Wendy, and Hamid, Saeed
- Published
- 2023
- Full Text
- View/download PDF
16. Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions
- Author
-
Jonas, Eduard, Bernon, Marc, Robertson, Barbara, Kassianides, Chris, Keli, Elie, Asare, Kwaku Offei, Alatise, Isaac Olusegun, Okello, Michael, Blondel, Nana Oumarou, Mulehane, Kenedy Ondede, Abubeker, Zeki Abdurahman, Nogoud, Alaaeldin Awad, Nashidengo, Pueya Rashid, Chihaka, Onesai, Tzeuton, Christian, Dusheiko, Geoffrey, Sonderup, Mark, and Spearman, C Wendy
- Published
- 2022
- Full Text
- View/download PDF
17. Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa
- Author
-
Spearman, C Wendy, Dusheiko, Geoffrey, Jonas, Eduard, Abdo, Abdelmounem, Afihene, Mary, Cunha, Lina, Desalegn, Hailemichael, Kassianides, Chris, Katsidzira, Leolin, Kramvis, Anna, Lam, Philip, Lesi, Olufunmilayo A, Micah, Eileen A, Musabeyezu, Emmanuel, Ndow, Gibril, Nnabuchi, Chidi V, Ocama, Ponsiano, Okeke, Edith, Rwegasha, John, Shewaye, Abate B, Some, Fatuma F, Tzeuton, Christian, and Sonderup, Mark W
- Published
- 2022
- Full Text
- View/download PDF
18. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
- Author
-
Blach, Sarah, Terrault, Norah A, Tacke, Frank, Gamkrelidze, Ivane, Craxi, Antonio, Tanaka, Junko, Waked, Imam, Dore, Gregory J, Abbas, Zaigham, Abdallah, Ayat R, Abdulla, Maheeba, Aghemo, Alessio, Aho, Inka, Akarca, Ulus S, Alalwan, Abduljaleel M, Alanko Blomé, Marianne, Al-Busafi, Said A, Aleman, Soo, Alghamdi, Abdullah S, Al-Hamoudi, Waleed K, Aljumah, Abdulrahman A, Al-Naamani, Khalid, Al Serkal, Yousif M, Altraif, Ibrahim H, Anand, Anil C, Anderson, Motswedi, Andersson, Monique I, Athanasakis, Kostas, Baatarkhuu, Oidov, Bakieva, Shokhista R, Ben-Ari, Ziv, Bessone, Fernando, Biondi, Mia J, Bizri, Abdul Rahman N, Brandão-Mello, Carlos E, Brigida, Krestina, Brown, Kimberly A, Brown, Jr, Robert S, Bruggmann, Philip, Brunetto, Maurizia R, Busschots, Dana, Buti, Maria, Butsashvili, Maia, Cabezas, Joaquin, Chae, Chungman, Chaloska Ivanova, Viktorija, Chan, Henry Lik Yuen, Cheinquer, Hugo, Cheng, Kent Jason, Cheon, Myeong-Eun, Chien, Cheng-Hung, Chien, Rong-Nan, Choudhuri, Gourdas, Christensen, Peer Brehm, Chuang, Wan-Long, Chulanov, Vladimir, Cisneros, Laura E, Coco, Barbara, Contreras, Fernando A, Cornberg, Markus, Cramp, Matthew E, Crespo, Javier, Cui, Fuqiang, Cunningham, Chris W, Dagher Abou, Lucy, Dalgard, Olav, Dao, Doan Y, De Ledinghen, Victor, Derbala, Moutaz F, Deuba, Keshab, Dhindsa, Karan, Djauzi, Samsuridjal, Drazilova, Sylvia, Duberg, Ann-Sofi, Elbadri, Mohammed, El-Sayed, Manal H, Esmat, Gamal, Estes, Chris, Ezzat, Sameera, Färkkilä, Martti A, Ferradini, Laurent, Ferraz, Maria Lucia G, Ferreira, Paulo R A, Filipec Kanizaj, Tajana, Flisiak, Robert, Frankova, Sona, Fung, James, Gamkrelidze, Amiran, Gane, Edward, Garcia, Virginia, García-Samaniego, Javier, Gemilyan, Manik, Genov, Jordan, Gheorghe, Liliana S, Gholam, Pierre M, Goldis, Adrian, Gottfredsson, Magnus, Gray, Richard T, Grebely, Jason, Gschwantler, Michael, Hajarizadeh, Behzad, Hamid, Saeed S, Hamoudi, Waseem, Hatzakis, Angelos, Hellard, Margaret E, Himatt, Sayed, Hofer, Harald, Hrstic, Irena, Hunyady, Bela, Husa, Petr, Husic-Selimovic, Azra, Jafri, Wasim S M, Janicko, Martin, Janjua, Naveed, Jarcuska, Peter, Jaroszewicz, Jerzy, Jerkeman, Anna, Jeruma, Agita, Jia, Jidong, Jonasson, Jon G, Kåberg, Martin, Kaita, Kelly D E, Kaliaskarova, Kulpash S, Kao, Jia-Horng, Kasymov, Omor T, Kelly-Hanku, Angela, Khamis, Faryal, Khamis, Jawad, Khan, Aamir G, Khandu, Lekey, Khoudri, Ibtissam, Kielland, Knut B, Kim, Do Young, Kodjoh, Nicolas, Kondili, Loreta A, Krajden, Mel, Krarup, Henrik Bygum, Kristian, Pavol, Kwon, Jisoo A, Lagging, Martin, Laleman, Wim, Lao, Wai Cheung, Lavanchy, Daniel, Lázaro, Pablo, Lazarus, Jeffrey V, Lee, Alice U, Lee, Mei-Hsuan, Li, Michael K K, Liakina, Valentina, Lim, Young-Suk, Löve, Arthur, Lukšić, Boris, Machekera, Shepherd Mufudzi, Malu, Abraham O, Marinho, Rui T, Maticic, Mojca, Mekonnen, Hailemichael D, Mendes-Correa, Maria Cássia, Mendez-Sanchez, Nahum, Merat, Shahin, Meshesha, Berhane Redae, Midgard, Håvard, Mills, Mike, Mohamed, Rosmawati, Mooneyhan, Ellen, Moreno, Christophe, Muljono, David H, Müllhaupt, Beat, Musabaev, Erkin, Muyldermans, Gaëtan, Nartey, Yvonne Ayerki, Naveira, Marcelo C M, Negro, Francesco, Nersesov, Alexander V, Njouom, Richard, Ntagirabiri, Rénovat, Nurmatov, Zuridin S, Obekpa, Solomon A, Oguche, Stephen, Olafsson, Sigurdur, Ong, Janus P, Opare-Sem, Ohene K, Orrego, Mauricio, Øvrehus, Anne L, Pan, Calvin Q, Papatheodoridis, George V, Peck-Radosavljevic, Markus, Pessoa, Mário G, Phillips, Richard O, Pimenov, Nikolay, Plaseska-Karanfilska, Dijana, Prabdial-Sing, Nishi N, Puri, Pankaj, Qureshi, Huma, Rahman, Aninda, Ramji, Alnoor, Razavi-Shearer, Devin M, Razavi-Shearer, Kathryn, Ridruejo, Ezequiel, Ríos-Hincapié, Cielo Y, Rizvi, S M Shahriar, Robaeys, Geert K M M, Roberts, Lewis R, Roberts, Stuart K, Ryder, Stephen D, Sadirova, Shakhlo, Saeed, Umar, Safadi, Rifaat, Sagalova, Olga, Said, Sanaa S, Salupere, Riina, Sanai, Faisal M, Sanchez-Avila, Juan F, Saraswat, Vivek A, Sarrazin, Christoph, Sarybayeva, Gulya, Seguin-Devaux, Carole, Sharara, Ala I, Sheikh, Mahdi, Shewaye, Abate B, Sievert, William, Simojoki, Kaarlo, Simonova, Marieta Y, Sonderup, Mark W, Spearman, C Wendy, Sperl, Jan, Stauber, Rudolf E, Stedman, Catherine A M, Su, Tung-Hung, Suleiman, Anita, Sypsa, Vana, Tamayo Antabak, Natalia, Tan, Soek-Siam, Tergast, Tammo L, Thurairajah, Prem H, Tolmane, Ieva, Tomasiewicz, Krzysztof, Tsereteli, Maia, Uzochukwu, Benjamin S C, Van De Vijver, David A M C, Van Santen, Daniela K, Van Vlierberghe, Hans, Van Welzen, Berend, Vanwolleghem, Thomas, Vélez-Möller, Patricia, Villamil, Federico, Vince, Adriana, Waheed, Yasir, Weis, Nina, Wong, Vincent W-S, Yaghi, Cesar G, Yesmembetov, Kakharman, Yosry, Ayman, Yuen, Man-Fung, Yunihastuti, Evy, Zeuzem, Stefan, Zuckerman, Eli, and Razavi, Homie A
- Published
- 2022
- Full Text
- View/download PDF
19. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
- Author
-
Rouabhia, Samir, Ghazinyan, Hasmik, Iskandar, Natacha Jreige, Trauner, Michael, Aghayeva, Gulnara, Carter, Flloyd, Sridharan, Kannan, Al Mahtab, Mamun, Francque, Sven, Kodjoh, Nicolas, Camacho, Ruben Muñoz, Anderson, Motswedi, Marques Souza de Oliveira, Claudia Pinto, Mateva, Lyudmila, Serme, Abdel Karim, Soares Martins, Antonieta A., Swain, Mark G., Komas, Narcisse Patrice, Zheng, Ming-Hua, Jaramillo, Patricio Lopez, Murillo, Omar Alfaro, Mikolasevic, Ivana, Vounou, Emmelia, Brůha, Radan, Nlombi, Charles Mbendi, Thiele, Maja, Perez, Marlene, Suárez M, Juan José, Waked, Imam, Salupere, Riina, Desalegn, Hailemichael, Yki-Järvinen, Hannele, Tsertsvadze, Tengiz, Sharvadze, Lali, Butsashvili, Maia, Awuku, Yaw Asante, Papatheodoridis, Georgios, Hunyady, Bela, Bjornsson, Einar Stefan, Duseja, Ajay, Lesmana, Cosmas Rinaldi A., Malekzadeh, Reza, Norris, Suzanne, Koike, Kazuhiko, Nersesov, Alexander V., Ochwoto, Missiani, Jamal, Mohammad, Saparbu, Tobokalova, Tolmane, Ieva, Sayegh, Raymond, Sheriff, Dhastagir Sultan, Valantinas, Jonas, Weber, Joseph, Shawa, Isaac Thom, Tan, Soek-Siam, Martínez Vázquez, Sophia E., Baatarkhuu, Oidov, Lkhagvaa, Undram, Jadamba, Tsolmon, Mohammed, Tahiri, Sudhamshu, K.C, Coppell, Kirsten, Onyekwere, Charles, Nikolova, Dafina, Vesterhus, Mette, Al-Naamani, Khalid, Hamid, Saeed, Méndez, Juan Paredes, Cabrera Cabrejos, María Cecilia, Flisiak, Robert, Torres, Esther A., Taheri, Shahrad, Sung, Ki-Chul, Adela, Turcanu, Gheorghe, Liana, Sanai, Faisal M., Milovanovic, Tamara, Bee Goh, George Boon, Rac, Marek, Dassanayake, Anuradha, Osama, Shahinaz Bedri, Elsanousi, M., Dufour, Jean-François, Kao, Jia-Horng, Saidi, Dilshod, Treeprasertsuk, Sombat, Koek, Ger, Labidi, Asma, Skrypnyk, Igor, AlKhatry, Maryam Salem, Sadirova, Shakhlo, Bakieva, Shokhista, Sinkala, Edford, Lazarus, Jeffrey V., Mark, Henry E., Villota-Rivas, Marcela, Palayew, Adam, Carrieri, Patrizia, Colombo, Massimo, Ekstedt, Mattias, Esmat, Gamal, George, Jacob, Marchesini, Giulio, Novak, Katja, Ocama, Ponsiano, Ratziu, Vlad, Razavi, Homie, Romero-Gómez, Manuel, Silva, Marcelo, Spearman, C. Wendy, Tacke, Frank, Tsochatzis, Emmanuel A., Yilmaz, Yusuf, Younossi, Zobair M., Wong, Vincent W.-S., Zelber-Sagi, Shira, Cortez-Pinto, Helena, and Anstee, Quentin M.
- Published
- 2022
- Full Text
- View/download PDF
20. Epidemiology, risk factors, social determinants of health, and current management for non-alcoholic fatty liver disease in sub-Saharan Africa
- Author
-
Spearman, C Wendy, Afihene, Mary, Betiku, Omolade, Bobat, Bilal, Cunha, Lina, Kassianides, Chris, Katsidzira, Leolin, Mekonnen, Hailemichael D, Ocama, Ponsiano, Ojo, Olusegun, Paruk, Imran, Tzeuton, Christian, and Sonderup, Mark W
- Published
- 2021
- Full Text
- View/download PDF
21. Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa
- Author
-
Spearman, C Wendy, Abdo, Abdelmounem, Ambali, Aggrey, Awuku, Yaw A, Kassianides, Chris, Lesi, Olufunmilayo A, Ndomondo-Sigonda, Margareth, Onyekwere, Charles A, Rwegasha, John, Shewaye, Abate B, and Sonderup, Mark W
- Published
- 2021
- Full Text
- View/download PDF
22. Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study
- Author
-
Seaman, Christopher P, Morgan, Christopher, Howell, Jess, Xiao, Yinzong, Spearman, C Wendy, Sonderup, Mark, Lesi, Olufunmilayo, Andersson, Monique I, Hellard, Margaret E, and Scott, Nick
- Published
- 2020
- Full Text
- View/download PDF
23. Hepatitis C
- Author
-
Spearman, C Wendy, Dusheiko, Geoffrey M, Hellard, Margaret, and Sonderup, Mark
- Published
- 2019
- Full Text
- View/download PDF
24. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
- Author
-
Abdo, Ayman, Aggarwal, Rakesh, Aghemo, Alessio, Al-Judaibi, Bandar, Al Mahtab, Mamun, Altaf, Arshad, Ameen, Zyaad, Asselah, Tarik, Baatarkkhuu, Oidov, Barber, Ella, Barnes, Eleanor, Boulet, Pascale, Burrows, Louise, Butsashvili, Maia, Chan, Erica, Chow, Chelsea, Cowie, Ben, Cunningham, Chris, de Araujo, Alexandre, Diap, Graciela, Dore, Greg, Doyle, Joseph, Elsayed, Manal, Fajardo, Emmanuel, Gane, Ed, Getahun, Aneley, Goldberg, David, Got, Tiffany, Hickman, Matthew, Hill, Andrew, Hutchinson, Sharon, Jones, Chris, Kamili, Saleem, Khan, Amreen, Lee, Alice, Lee, Tin Yan, Malani, Jioiji, Morris, Tammy Meyers, Nayagam, Shevanthi, Njouom, Richard, Ocama, Ponsiano, Pedrana, Alisa, Peeling, Rosanna, Reddy, Amulya, Sacks, Jilian, Sarin, Shiv, Shimakawa, Yusuke, Silva, Marcela, Skala, Pavlo, Taylor-Robinson, Simon, Thompson, Alex, Thursz, Mark, Tonganibeia, Alfred, Wallace, Jack, Ward, James, Wolff, Fernando, Vickerman, Peter, Yau, Johnny, Cooke, Graham S, Andrieux-Meyer, Isabelle, Applegate, Tanya L, Atun, Rifat, Burry, Jessica R, Cheinquer, Hugo, Dusheiko, Geoff, Feld, Jordan J, Gore, Charles, Griswold, Max G, Hamid, Saeed, Hellard, Margaret E, Hou, JinLin, Howell, Jess, Jia, Jidong, Kravchenko, Natalia, Lazarus, Jeffrey V, Lemoine, Maud, Lesi, Olufunmilayo A, Maistat, Liudmyla, McMahon, Brian J, Razavi, Homie, Roberts, Teri, Simmons, Bryony, Sonderup, Mark W, Spearman, C Wendy, Taylor, Bridie E, Thomas, David L, Waked, Imam, Ward, John W, and Wiktor, Stefan Z
- Published
- 2019
- Full Text
- View/download PDF
25. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study
- Author
-
Scott, Nick, Palmer, Anna, Morgan, Christopher, Lesi, Olufunmilayo, Spearman, C Wendy, Sonderup, Mark, and Hellard, Margaret
- Published
- 2018
- Full Text
- View/download PDF
26. Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets
- Author
-
Spearman, C Wendy, Afihene, Mary, Ally, Reidwaan, Apica, Betty, Awuku, Yaw, Cunha, Lina, Dusheiko, Geoffrey, Gogela, Neliswa, Kassianides, Chris, Kew, Michael, Lam, Philip, Lesi, Olufunmilayo, Lohouès-Kouacou, Marie-Jeanne, Mbaye, Papa Saliou, Musabeyezu, Emmanuel, Musau, Betty, Ojo, Olusegun, Rwegasha, John, Scholz, Barbara, Shewaye, Abate B, Tzeuton, Christian, and Sonderup, Mark W
- Published
- 2017
- Full Text
- View/download PDF
27. Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030
- Author
-
Sonderup, Mark W, Afihene, Mary, Ally, Reidwaan, Apica, Betty, Awuku, Yaw, Cunha, Lina, Dusheiko, Geoffrey, Gogela, Neliswa, Lohouès-Kouacou, Marie-Jeanne, Lam, Phillip, Lesi, Olufunmilayo, Mbaye, Papa Saliou, Musabeyezu, Emmanuel, Musau, Betty, Ojo, Olesegun, Rwegasha, John, Scholz, Barbara, Shewaye, Abate B, Tzeuton, Christian, Kassianides, Chris, and Spearman, C Wendy
- Published
- 2017
- Full Text
- View/download PDF
28. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017)
- Author
-
Scheibe, Andrew, Young, Katherine, Versfeld, Anna, Spearman, C. Wendy, Sonderup, Mark W., Prabdial-Sing, Nishi, Puren, Adrian, and Hausler, Harry
- Published
- 2020
- Full Text
- View/download PDF
29. Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities
- Author
-
Versfeld, Anna, McBride, Angela, Scheibe, Andrew, and Spearman, C. Wendy
- Published
- 2020
- Full Text
- View/download PDF
30. HBV elimination in Africa-Current status and challenges.
- Author
-
Sonderup, Mark W. and Spearman, C. Wendy
- Published
- 2024
- Full Text
- View/download PDF
31. Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum
- Author
-
Heffernan, Alastair, Barber, Ella, Cook, Nicola A, Gomaa, Asmaa I, Harley, Yolande X, Jones, Christopher R, Lim, Aaron G, Mohamed, Zameer, Nayagam, Shevanthi, Ndow, Gibril, Shah, Rajiv, Sonderup, Mark W, Spearman, C Wendy, Waked, Imam, Wilkinson, Robert J, and Taylor-Robinson, Simon D
- Published
- 2018
- Full Text
- View/download PDF
32. A new approach to prevent, diagnose, and treat hepatitis B in Africa.
- Author
-
Spearman, C. Wendy, Andersson, Monique I., Bright, Bisi, Davwar, Pantong M., Desalegn, Hailemichael, Guingane, Alice Nanelin, Johannessen, Asgeir, Kabagambe, Kenneth, Lemoine, Maud, Matthews, Philippa C., Ndow, Gibril, Riches, Nicholas, Shimakawa, Yusuke, Sombié, Roger, Stockdale, Alexander J., Taljaard, Jantjie J., Vinikoor, Michael J., Wandeler, Gilles, Okeke, Edith, and Sonderup, Mark
- Subjects
- *
HEPATITIS B treatment , *HEPATITIS B prevention , *HEPATITIS B vaccines , *TENOFOVIR , *LIVER cancer , *CIRRHOSIS of the liver - Abstract
There are 82 million people living with hepatitis B (PLWHB) in the World Health Organization Africa region, where it is the main cause of liver disease. Effective vaccines have been available for over 40 years, yet there are 990,000 new infections annually, due to limited implementation of hepatitis B birth dose vaccination and antenatal tenofovir prophylaxis for highly viraemic women, which could eliminate mother-to-child transmission. Despite effective and cheap antiviral treatment which can suppress hepatitis B virus replication and reduce the risk of hepatocellular carcinoma (HCC), < 2% of PLWHB are diagnosed, and only 0.1% are treated. As a result, PLWHB are frequently diagnosed only when they have already developed decompensated cirrhosis and late-stage HCC, and consequently 80,000 hepatitis B-associated deaths occur each year. Major barriers include complex treatment guidelines which were derived from high-income settings, lack of affordable diagnostics, lack or insufficient domestic funding for hepatitis care, and limited healthcare infrastructure. Current treatment criteria may overlook patients at risk of cirrhosis and HCC. Therefore, expanded and simplified treatment criteria are needed. We advocate for decentralized community treatment programmes, adapted for low-resource and rural settings with limited laboratory infrastructure. We propose a strategy of treat-all except patients fulfilling criteria that suggest low risk of disease progression. Expanded treatment represents a financial challenge requiring concerted action from policy makers, industry, and international donor agencies. It is crucial to accelerate hepatitis B elimination plans, integrate hepatitis B care into existing healthcare programmes, and prioritize longitudinal and implementation research to improve care for PLWHB. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Informing a target product profile for rapid tests to identify HBV-infected pregnant women with high viral loads: a discrete choice experiment with African healthcare workers.
- Author
-
Isa, Yasir Shitu, Sicsic, Jonathan, Njuguna, Henry, Ward, John, Chakroun, Mohamed, El-Kassas, Mohamed, Ramanampamonjy, Rado, Chalal, Salim, Vincent, Jeanne Perpétue, Andersson, Monique, Desalegn, Hailemichael, Fall, Fatou, Johannessen, Asgeir, Matthews, Philippa C., Ndow, Gibril, Okeke, Edith, Riches, Nicholas, Seydi, Moussa, Sinkala, Edford, and Spearman, C. Wendy
- Subjects
MEDICAL personnel ,RAPID diagnostic tests ,VIRAL load ,PREGNANT women ,HEPATITIS B virus - Abstract
Background: Elimination of mother-to-child transmission of hepatitis B virus (HBV) requires infant immunoprophylaxis and antiviral prophylaxis for pregnant women with high viral loads. Since real-time polymerase chain reaction (RT-PCR), a gold standard for assessing antiviral eligibility, is neither accessible nor affordable for women living in low-income and middle-income countries (LMICs), rapid diagnostic tests (RDTs) detecting alternative HBV markers may be needed. To inform future development of the target product profile (TPP) for RDTs to identify highly viremic women, we used a discrete choice experiment (DCE) and elicited preference and trade-off of healthcare workers (HCW) in Africa between the following four attributes of fictional RDTs: price, time-to-result, diagnostic sensitivity, and specificity. Methods: Through an online questionnaire survey, we asked participants to indicate their preferred test from a set of two RDTs in seven choice tasks with varying levels of the four attributes. We used mixed multinomial logit models to quantify the utility gain or loss generated by each attribute. We attempted to define minimal and optimal criteria for test attributes that can satisfy ≥ 70% and ≥ 90% of HCWs, respectively, as an alternative to RT-PCR. Results: A total of 555 HCWs from 41 African countries participated. Increases in sensitivity and specificity generated significant utility and increases in cost and time-to-result generated significant disutility. The size of the coefficients for the highest attribute levels relative to the reference levels were in the following order: sensitivity (β = 3.749), cost (β = -2.550), specificity (β = 1.134), and time-to-result (β = -0.284). Doctors cared most about test sensitivity, while public health practitioners cared about cost and midwives about time-to-result. For an RDT with 95% specificity, costing 1 US$, and yielding results in 20 min, the minimally acceptable test sensitivity would be 82.5% and the optimally acceptable sensitivity would be 87.5%. Conclusions: African HCWs would prefer an RDT with the following order of priority: higher sensitivity, lower cost, higher specificity, and shorter time-to-result. The development and optimization of RDTs that can meet the criteria are urgently needed to scale up the prevention of HBV mother-to-child transmission in LMICs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting - HIV/viral hepatitis: improving diagnosis, antiviral therapy and access
- Author
-
Maponga, Tongai G., Matteau Matsha, Rachel, Morin, Sébastien, Scheibe, Andrew, Swan, Tracy, Andrieux-Meyer, Isabelle, Spearman, C. Wendy, Klein, Marina B., and Rockstroh, Jürgen Kurt
- Published
- 2017
- Full Text
- View/download PDF
35. The performance of hepatitis C virus (HCV) antibody point‐of‐care tests on oral fluid or whole blood and dried blood spot testing for HCV serology and viral load among individuals at higher risk for HCV in South Africa
- Author
-
Prabdial‐Sing, Nishi, Gaelejwe, Lucinda, Makhathini, Lillian, Thaver, Jayendrie, Manamela, Morubula Jack, Malfeld, Susan, Spearman, C. Wendy, Sonderup, Mark, Scheibe, Andrew, Young, Katherine, Hausler, Harry, and Puren, Adrian J.
- Subjects
screening ,HCV ,point‐of‐care ,Medicine ,high risk ,dried blood spot ,Research Articles ,Research Article - Abstract
Background and Aims To enhance screening and diagnosis in those at‐risk of hepatitis C virus (HCV), efficient and improved sampling and testing is required. We investigated the performance of point‐of‐care (POC) tests and dried blood spots (DBS) for HCV antibody and HCV RNA quantification in individuals at higher risk for HCV (people who use and inject drugs, sex workers and men who have sex with men) in seven South African cities. Methods Samples were screened on the OraQuick HCV POC test (471 whole blood and 218 oral fluid); 218 whole blood and DBS paired samples were evaluated on the ARCHITECT HCV antibody (Abbott) and HCV viral load (COBAS Ampliprep/COBAS TaqMan version 2) assays. For HCV RNA quantification, 107 dB were analyzed with and without normalization coefficients. Results POC on either whole blood or oral fluid showed an overall sensitivity of 98.5% (95% CI 97.4‐99.5), specificity of 98.2% (95% CI 98.8‐100) and accuracy of 98.4% (95% CI 96.5‐99.3). On the antibody immunoassay, DBS showed a sensitivity of 96.0% (95% CI 93.4‐98.6), specificity of 97% (95% CI 94.8‐99.3) and accuracy of 96.3% (95% CI 93.8‐98.8). A strong correlation (R 2 = 0.90) between viral load measurements for DBS and plasma samples was observed. After normalization, DBS viral load results showed an improved bias from 0.5 to 0.16 log10 IU/mL. Conclusion The POC test performed sufficiently well to be used for HCV screening in at‐risk populations. DBS for diagnosis and quantification was accurate and should be considered as an alternative sample to test. POC and DBS can help scale up hepatitis services in the country, in light of our elimination goals.
- Published
- 2021
36. OS-016 Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVEtrial.
- Author
-
Sonderup, Mark, Spearman, C Wendy, Calvaruso, Vincenza, Antunes, Nuno, Shu, Jianfen, Zein, Claudia O., and Kowdley, Kris V.
- Published
- 2024
- Full Text
- View/download PDF
37. Hepatitis B in sub‐Saharan Africa—How many patients need therapy?
- Author
-
Sonderup, Mark W., Dusheiko, Geoffrey, Desalegn, Hailemichael, Lemoine, Maud, Tzeuton, Christian, Taylor‐Robinson, Simon D., and Spearman, C. Wendy
- Subjects
HEPATITIS B ,CHRONIC hepatitis B ,DRUG accessibility ,VACCINATION - Abstract
Hepatitis B is endemic in sub‐Saharan Africa with ~60 million people chronically infected. While prevention, through vaccination, is central to elimination strategies, only 11 countries have birth dose vaccination and full vaccine coverage remains at suboptimal levels. Furthermore, to fully realize elimination, those chronically infected need to be identified, assessed for therapy and then linked to care. Given current treatment criteria, the precise quantum of people warranting therapy, according to criteria, is essentially unknown. The issue is further complicated by data to suggest differences in the numbers of people requiring treatment when applying WHO as compared to European Association for the Study of the Liver, EASL, criteria. Optimal determination of treatment eligibility is further hindered by the lack of available tools to adequately assess individual patients. It is conceivable that accurately determining the number of those requiring treatment, given the heterogeneity of hepatitis B in Africa, is difficult. Better studies and data are required. More signifcantly, improved access and availability to the diagnostic tools needed to assess patients in additon to access to drugs are as, if not more important, to achieve elimination. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
- Author
-
Spearman, C. Wendy, Desalegn, Hailemichael, Ocama, Ponsiano, Awuku, Yaw Asante, Ojo, Olusegun, Elsahhar, Medhat, Abdo, Abdulmunem A., Ndububa, Dennis Amajuoyi, Fouad, Yasser, Borodo, Musa Muhammed, Ng'wanasayi, Masolwa, Ally, Reidwan, and Elwakil, Reda
- Subjects
- *
FATTY liver - Published
- 2021
- Full Text
- View/download PDF
39. Molecular characterisation of acute intermittent porphyria in a cohort of South African patients and kinetic analysis of two expressed mutants.
- Author
-
Fortgens, Philip, Pienaar, Elaine, Corrigall, Anne, Sonderup, Mark, Spearman, C. Wendy, and Meissner, Peter
- Subjects
ACUTE intermittent porphyria ,GENE expression ,MOLECULAR biology ,SOUTH Africans ,SYNTHASE genetics ,DIAGNOSIS ,DISEASES - Published
- 2017
- Full Text
- View/download PDF
40. Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population.
- Author
-
Gencay, Mikael, Hübner, Kirsten, Gohl, Peter, Seffner, Anja, Weizenegger, Michael, Neofytos, Dionysios, Batrla, Richard, Woeste, Andreas, Kim, Hyon-suk, Westergaard, Gaston, Reinsch, Christine, Brill, Eva, Thu Thuy, Pham Thi, Hoang, Bui Huu, Sonderup, Mark, Spearman, C. Wendy, Pabinger, Stephan, Gautier, Jérémie, Brancaccio, Giuseppina, and Fasano, Massimo
- Subjects
HEPATITIS associated antigen ,HEPATITIS B ,MEDICAL screening ,ANTIGENS ,CELL surface antigens ,HEPATITIS B virus ,DIAGNOSIS - Abstract
The diversity of the hepatitis B surface antigen (HBsAg) has a significant impact on the performance of diagnostic screening tests and the clinical outcome of hepatitis B infection. Neutralizing or diagnostic antibodies against the HBsAg are directed towards its highly conserved major hydrophilic region (MHR), in particular towards its “a” determinant subdomain. Here, we explored, on a global scale, the genetic diversity of the HBsAg MHR in a large, multi-ethnic cohort of randomly selected subjects with HBV infection from four continents. A total of 1553 HBsAg positive blood samples of subjects originating from 20 different countries across Africa, America, Asia and central Europe were characterized for amino acid variation in the MHR. Using highly sensitive ultra-deep sequencing, we found 72.8% of the successfully sequenced subjects (n = 1391) demonstrated amino acid sequence variation in the HBsAg MHR. This indicates that the global variation frequency in the HBsAg MHR is threefold higher than previously reported. The majority of the amino acid mutations were found in the HBV genotypes B (28.9%) and C (25.4%). Collectively, we identified 345 distinct amino acid mutations in the MHR. Among these, we report 62 previously unknown mutations, which extends the worldwide pool of currently known HBsAg MHR mutations by 22%. Importantly, topological analysis identified the “a” determinant upstream flanking region as the structurally most diverse subdomain of the HBsAg MHR. The highest prevalence of “a” determinant region mutations was observed in subjects from Asia, followed by the African, American and European cohorts, respectively. Finally, we found that more than half (59.3%) of all HBV subjects investigated carried multiple MHR mutations. Together, this worldwide ultra-deep sequencing based genotyping study reveals that the global prevalence and structural complexity of variation in the hepatitis B surface antigen have, to date, been significantly underappreciated. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
41. Hepatitis C treatment: where are we now?
- Author
-
Burstow, Nicholas J., Mohamed, Zameer, Gomaa, Asmaa I., Sonderup, Mark W., Cook, Nicola A., Waked, Imam, Spearman, C. Wendy, and Taylor-Robinson, Simon D.
- Subjects
HEPATITIS C diagnosis ,INFLAMMATION ,INTERFERONS ,RIBAVIRIN ,DRUG efficacy - Abstract
Chronic hepatitis C infection affects millions of people worldwide and confers significant morbidity and mortality. Effective treatment is needed to prevent disease progression and associated complications. Previous treatment options were limited to interferon and ribavirin (RBV) regimens, which gave low cure rates and were associated with unpleasant side effects. The era of direct-acting antiviral (DAA) therapies began with the development of first-generation NS3/4A protease inhibitors in 2011. They vastly improved outcomes for patients, particularly those with genotype 1 infection, the most prevalent genotype globally. Since then, a multitude of DAAs have been licensed for use, and outcomes for patients have improved further, with fewer side effects and cure rates approaching 100%. Recent regimens are interferon-free, and in many cases, RBV-free, and involve a combination of DAA agents. This review summarizes the treatment options currently available and discusses potential barriers that may delay the global eradication of hepatitis C. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
42. N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review.
- Author
-
Chughlay, Mohamed Farouk, Kramer, Nicole, Spearman, C. Wendy, Werfalli, Mahmoud, and Cohen, Karen
- Subjects
ACETYLCYSTEINE ,DRUG side effects ,LIVER diseases ,BIOCHEMISTRY ,TRANSPLANTATION of organs, tissues, etc. - Abstract
Aims N-acetylcysteine (NAC) may be useful in the management of non-paracetamol drug-induced liver injury (DILI). Our objective was to review systematically evidence for the use of NAC as a therapeutic option for non-paracetamol DILI. Methods We searched for randomized controlled trials (RCTs) and prospective cohort studies. We searched several bibliographic databases, grey literature sources, conference proceedings and ongoing trials. Our pre-specified primary outcomes were all cause and DILI related mortality, time to normalization of liver biochemistry and adverse events. Secondary outcomes were proportion receiving liver transplant, time to transplantation, transplant-free survival and hospitalization duration. Results We identified one RCT of NAC vs. placebo in patients with non-paracetamol acute liver failure. There was no difference in the primary outcomes of overall survival at 3 weeks between NAC [70%, 95% confidence interval (CI) = 60%, 81%, n = 81] and placebo (66%, 95% CI = 56%, 77%, n = 92). NAC significantly improved the secondary outcomes of transplant-free survival compared with placebo: 40% NAC (95% CI = 28%, 51%) vs. 27% placebo (95% CI = 18%, 37%). A subgroup analysis according to aetiology found improved transplant-free survival in patients with non-paracetamol DILI, NAC (58%, n = 19) vs. placebo (27%, n = 26), odds ratio (OR) 0.27 (95% CI = 0.076, 0.942). Overall survival was similar, NAC (79%) vs. placebo (65%);, OR 0.50 (95% CI = 0.13, 1.98). Conclusion Current available evidence is limited and does not allow for any firm conclusions to be made regarding the role of NAC in non-paracetamol DILI. We therefore highlight the need for further research in this area. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
43. Health disparities in liver disease in sub-Saharan Africa.
- Author
-
Spearman, C. Wendy and Sonderup, Mark W.
- Subjects
- *
HEALTH equity , *LIVER disease prevention , *DISEASE prevalence , *PREVENTIVE medicine - Abstract
Disparities in health reflect the differences in the incidence, prevalence, burden of disease and access to care determined by socio-economic and environmental factors. With liver disease, these disparities are exacerbated by a combination of limited awareness and preventable causes of morbidity and mortality in addition to the diagnostic and management costs. Sub-Saharan Africa, comprising 11% of the world's population, disproportionately has 24% of the global disease burden, yet allocates <1% of global spend on health. It has 3% of the global healthcare workforce with a mean of 0.8 healthcare workers per 1000 population. Barriers to healthcare access are many and compounded by limited civil registration data, socio-economic inequalities, discrepancies in private and public healthcare services and geopolitical strife. The UN 2014 report on the Millennium Development Goals suggest that sub-Saharan Africa will probably not meet several goals, however with HIV/ AIDS and Malaria (goal 6), many successes have been achieved. A 2010 Global Burden of Disease study demonstrated that cirrhosis mortality in sub-Saharan Africa doubled between 1980 and 2010. Aetiologies included hepatitis B (34%), hepatitis C (17%), alcohol (18%) and unknown in 31%. Hepatitis B, C and alcohol accounted for 47, 23 and 20% of hepatocellular carcinoma respectively. In 10%, the underlying aetiology was not known. Liver disease reflects the broader disparities in healthcare in sub-Saharan Africa. However, many of these challenges are not insurmountable as vaccines and new therapies could comprehensively deal with the burden of viral hepatitis. Access to and affordability of therapeutics remains the major barrier. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
44. A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome.
- Author
-
Sonderup, Mark W., Wainwright, Helen, Hall, Pauline, Hairwadzi, Henry, and Spearman, C. Wendy N.
- Published
- 2015
- Full Text
- View/download PDF
45. Global Disparities in Hepatitis B Elimination—A Focus on Africa.
- Author
-
Sonderup, Mark W. and Spearman, C. Wendy
- Subjects
- *
DISEASE prevalence , *HEALTH equity , *PREGNANT women , *VACCINATION , *HEPATITIS B , *VIRAL hepatitis - Abstract
In 2016, WHO member states at the World Health Assembly adopted a Global Health Sector Strategy that included a policy of eliminating viral hepatitis. Clear targets were established to assist in achieving this by 2030. The strategy, while achievable, has exposed existing global disparities in healthcare systems and their ability to implement such policies. Compounding this, the regions with most disparity are also those where the hepatitis B prevalence and disease burden are the greatest. Foundational to hepatitis B elimination is the identification of both those with chronic infection and crucially pregnant women, and primary prevention through vaccination. Vaccination, including the birth dose and full three-dose coverage, is key, but complete mother-to-child transmission prevention includes reducing the maternal hepatitis B viral load in the third trimester where appropriate. Innovations and simplified tools exist in order to achieve elimination, but what is desperately required is the will to implement these strategies through the support of appropriate investment and funding. Without this, disparities will continue. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
- Author
-
Scheibe, Andrew, Young, Katherine, Moses, Lorraine, Basson, Rudolph L., Versfeld, Anna, Spearman, C. Wendy, Sonderup, Mark W., Prabdial-Sing, Nishi, Manamela, Jack, Puren, Adrian J., Rebe, Kevin, and Hausler, Harry
- Subjects
HEPATITIS C ,BLOODBORNE infections ,HIV infections ,HEPATITIS B ,HIV ,VIRAL load ,CELL surface antigens - Abstract
Background: People who inject drugs (PWID) are at high risk for hepatitis C (HCV), hepatitis B (HBV) and HIV without accessible harm reduction programmes. Coverage of needle and syringe and opioid substitution therapy (OST) services in South Africa is below global recommendations and no hepatitis services exist for PWID. We assessed HCV, HBV and HIV prevalence and risk factors among PWID accessing harm reduction services in Cape Town, Durban and Pretoria to inform policy and programming. Methods: We conducted a cross-sectional survey among PWID in these cities between August 2016 and October 2017. Participants were opportunistically sampled while accessing services. Study team members administered a questionnaire that assessed sociodemographic characteristics, drug use and sexual risk practices. We tested for HCV (antibody, viral load and genotype), HBV surface antigen (HBsAg) and HIV. Bivariate and multivariate analyses assessed associations with HCV serostatus. Results: Nine hundred and forty-three PWID were included in the per protocol analysis. The majority (87%, 819/943) were male, the overall median age was 29 and most lived on the street (66%, 626/943). At last injection, 77% (722/943) reported using a new needle and syringe and 17% (163/943) shared equipment. HIV prevalence was 21% (196/926), HBsAg positivity 5% (47/936), HCV seroprevalence 55% (513/937), HCV viraemic prevalence (proportion tested with detectable HCV) 43% (404/937) and HCV viraemic rate (proportion HCV antibody positive with detectable HCV) 79% (404/513). HCV genotype 1a (73%, 270/368) was the most prevalent. In multivariate analysis, HCV infection was positively associated with residing in Pretoria (adjusted odds ratio (aOR) 1.27, 95% CI 1.21–1.34), living on the street (aOR 1.90, 95% CI 1.38–2.60), frequent injecting (aOR 1.58, 95% CI 1.15–2.16) and HIV infection (aOR 1.69, 95% CI 1.15–2.47), and negatively associated with black race (aOR 0.52, 95% CI 0.36–0.74) and sexual activity in the previous month (aOR 0.61, 95% CI 0.42–0.88). Conclusions: HCV and HIV are major health threats affecting PWID in these cities. Access to OST and needle and syringe services needs to be increased and integrated with HCV services. Social and structural factors affecting PWID who live on the street need to be addressed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
47. Guidelines for the use of Transient Elastography in South Africa.
- Author
-
Sonderup, Mark, Gogela, Neliswa, and Spearman, C. Wendy
- Subjects
- *
ELASTOGRAPHY , *VIRAL hepatitis , *LIVER biopsy , *LIVER disease treatment , *FATTY liver - Abstract
Liver fibrosis assessment is key to rapid decision making with respect to treatment and prognosis in liver disease • Liver biopsy remains the gold standard for assessing fibrosis and pattern of injury but is invasive, costly, relatively unavailable and is unsuited to the rapid and efficient upscaling of treatment to those in need of care e.g. viral hepatitis • Non invasive technologies are supplanting liver biopsy as the primary means of assessing liver fibrosis • Transient elastography (FibroScan®) - first introduced in 2003 - has evolved as a reliable and validated noninvasive technology for assessing liver fibrosis • The technique is simple and requires easily transferrable operator skills • A minimum of 10 readings are required to be valid • Substantial data supports its validity in a variety of chronic liver diseases with AUROC scores that range between 0.85 and 0.95 • FibroScan® has the added benefit of assessing fatty change in the liver via the CAP (Controlled Attenuation Parameter) assessment score • Potential users of this technology should acquire the requisite upskilling to operate Transient Elastography (FibroScan®) • To achieve the objectives of the National Viral Hepatitis Elimination Strategy in South Africa, such technology will be needed in the public sector • The cost effectiveness of this technology with appropriate allocation of funding codes is required for the private sector. [ABSTRACT FROM AUTHOR]
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.